China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) announced that the National Medical Products Administration(NMPA) has accepted for review a market filing for its subsidiary Fosun Wanbang (Jiangsu) Pharmaceutical Group Co., Ltd.’s Category 1 chemical drug foritinib. This novel small molecule chemical drug is designed to treat non-small cell lung cancer (ALK+), non-small cell lung cancer (ROS1+), etc.
Clinical Development and NMPA Review
The drug is awaiting the NMPA’s decision as a treatment of anaplastic lymphoma kinase (ALK) positive locally advanced or metastatic non-small cell lung cancer (NSCLC). Co-developed by the Shanghai Institute of Materia Medica, Chinese Academy of Sciences in pre-clinical setting, the drug was licensed to Fosun for exclusive development and commercialization in mainland China where two Phase II studies for the drug in ROS1+ NSCLC have concluded.-Fineline Info & Tech
Leave a Reply